Researchers Reveal Adeno-to-squamous Transition as Mechanism for KRAS Inhibitor Resistance in LKB1 Mutant Lung Cancer
Researchers led by Prof. JI Hongbin from the Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences, and the collaborators, reported that AST drives the resistance to KRAS inhibition in LKB1-mutant lung cancer, and KRT6A is a predicative biomarker of poor KRAS inhibitor response.
Mar 01, 2024